Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. Articles
  3. of early detection during lung cancer
Show results for
News

Refine by
Date

  • Older

Of Early Detection During Lung Cancer Articles & Analysis

4 articles found

VisionGate’s Breakthrough Lung Cancer Detection Technologies Help Save Lives

VisionGate’s Breakthrough Lung Cancer Detection Technologies Help Save Lives

VisionGate’s Non-Intrusive Testing, Patented Cell-CT Imaging and AI-Powered Cancer Detection Work Together to Deliver Early Detection of Lung Cancer. VisionGate’s mission is backed by cutting-edge technology that is designed to save lives through early detection and prevention of lung cancer. VisionGate’s breakthrough technologies include non-intrusive testing, 3D cell imaging ...

ByVisionGate, Inc


VisionGate’s New Website Illustrates its Mission to Save Lives through Early Detection of Lung Cancer

VisionGate’s New Website Illustrates its Mission to Save Lives through Early Detection of Lung Cancer

VisionGate, a Breakthrough Liquid-biopsy Technology Company, Leads the Battle Against Lung Cancer through Early Detection Technology with a Simple, Non-Intrusive Sputum Test. VisionGate wants you to live your life with peace of mind. That’s why we’ve launched a new website that makes it easy for you to learn more about our advanced lung cancer detection technology. Our new site ...

ByVisionGate, Inc


VisionGate’s Abstract Accepted for the 2021 World Conference on Lung Cancer: COPD and LuCED Performance

VisionGate’s Abstract Accepted for the 2021 World Conference on Lung Cancer: COPD and LuCED Performance

The Non-Intrusive LuCED Test for Detection of Early-Stage Lung Cancer: A Subgroup Analysis for Chronic Obstructive Pulmonary Disease (COPD) Introduction VisionGate’s LuCED® test for lung cancer measures 934 features in each cell imaged in 3D by the Cell- CT™. Sensitivity and specificity, both exceeding 90%, have been reported (Wilbur, et. al., Cancer Cytopathology, ...

ByVisionGate, Inc


Spanish Cancer Company Universal Dx to Commercialize Methylation Method for Lung Cancer Detection

Spanish Cancer Company Universal Dx to Commercialize Methylation Method for Lung Cancer Detection

NEW YORK - Spanish cancer research firm Universal Diagnostics is gearing up to commercialize a liquid biopsy test that applies methylation biomarkers to detect lung cancer, based on data presented at the International Association for the Study of Lung Cancer 2020 World Conference for Lung Cancer (WCLC) last month. The Seville-based firm also expects to release clinical data on its next ...

ByUniversal Diagnostics SL

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT